Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (12): 1408-1414.doi: 10.12092/j.issn.1009-2501.2018.12.016

Previous Articles     Next Articles

Effects of Yishen Kangliu recipe in combination with IL-2 peritoneal perfusion in treatment of ovarian cancer-associated ascites

CHEN Xiangyan1, CHEN Cong2, SUN Yun1, ZHANG Hong1, GAO Chuchu1, CHEN Shu1   

  1. 1 Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang, China; 2 Wenzhou People's Hospital, Wenzhou 325000, Zhejiang, China
  • Received:2018-08-13 Revised:2018-11-08 Online:2018-12-26 Published:2018-12-27

Abstract:

AIM: To investigate the therapeutic effect of Yishen Kangliu recipe combined with IL-2 peritoneal perfusion on advanced ovarian cancer-related ascites. METHODS: Ninety-eight cases of ovarian cancer-related ascites were divided into experimental group (49 cases) and control group (49 cases) by random number table. Both groups were treated with paclitaxel combined with carboplatin. On the basis of this, the control group was given intraperitoneal infusion of IL-2, while the experimental group IL-2 intraperitoneal perfusion combined with Yishen Kangliu receipe treatment. The effective rate of ascites control, CEA, CA125, HE4, VEGF, T lymphocyte subsets, IgA, IgM, IgG level changes, adverse reactions and Karnofsky score changes, and PFS of the groups were compared. RESULTS: The total effective rate of the experimental group was significantly higher than that of the control group (P<0.05). The total remission rate and control rate of CA125 in the experimental group were 71.4% and 95.9% respectively, which were significantly higher than 46.9% and 83.7% in the control group (P<0.05). After treatment, the levels of CEA, CA125, HE4 and VEGF in the experimental group were significantly lower than those before treatment and after the control group (P<0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+, NK cells and IgM, IgG in the experimental group were significantly higher than those before treatment, and the experimental group was significantly higher than the control group (P<0.05). Gastrointestinal reactions, leukopenia, thrombocytopenia, elevated transaminases, elevated urea nitrogen and peripheral neurological symptoms in the experimental group were significantly lower than those in the control group (P<0.05). PFS in the experimental group was 6.0 (3-12) months, which was significantly longer than that in the control group 4.0 (2-10) months (χ2=8.113, P<0.01). CONCLUSION: Yishen Kangliu recipe combined with IL-2 intraperitoneal perfusion in the treatment of ovarian cancer complicated with malignant ascites i can effectively inhibit the proliferation of tumor cells and improve the quality of life of patients with high safety.

Key words: Yishen Kangliu recipe, interleukin-2, ovarian cancer-related ascites, immune function

CLC Number: